Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778709 | 0.90 | KDR (0.47) | MKNK1EGFRKDRRETSYK | |
| SCHEMBL13060922 | 0.81 | MAPT (0.45) | — | |
| SCHEMBL3770441 | 0.80 | GRM4 (0.61) | EGFR | |
| SCHEMBL381085 | 0.79 | GRM4 (0.62) | EGFRKDRERBB2SYK | |
| SCHEMBL3775329 | 0.79 | LRRK2 (0.61) | EGFRKDR | |
| SCHEMBL13006164 | 0.79 | LRRK2 (0.44) | — | |
| SCHEMBL3775905 | 0.79 | LRRK2 (0.46) | — | |
| SCHEMBL3762265 | 0.79 | GRM4 (0.54) | KDR | |
| SCHEMBL3774600 | 0.78 | LRRK2 (0.44) | — | |
| SCHEMBL28591601 | 0.78 | MAPKAPK2 (0.60) | MKNK1MAPKAPK2EGFRROCK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | MKNK1 4235/4885MAPKAPK2 4302/4885EGFR 106/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | MKNK1 4259/4885MAPKAPK2 4307/4885EGFR 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.